PPARγ activation in adipocytes is sufficient for systemic insulin sensitization

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 52, 2009, Pages 22504-22509

  Sugii, Shigeki ^a,b   Olson, Peter ^a,c   Sears, Dorothy D ^d   Saberi, Maziyar ^d   Atkins, Annette R ^a   Barish, Grant D ^a   Hong, Suk Hyun ^a   Castro, Glenda L ^a   Yin, Yun Qiang ^a   Nelson, Michael C ^a,b   Hsiao, Gene ^e   Greaves, David R ^f   Downes, Michael ^a   Yu, Ruth T ^a   Olefsky, Jerrold M ^d   Evans, Ronald M ^a,b,c  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Inflammation; Insulin signaling; Metabolic syndrome; Nuclear hormone receptors

Indexed keywords

ADIPOCYTOKINE; AG 035029; CARBOHYDRATE; CD36 ANTIGEN; CD68 ANTIGEN; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULIN SENSITIZING AGENT; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROTEIN KINASE B; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; AUTACOID; CHEMOKINE; HYBRID PROTEIN;

ADIPOCYTE; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSGENIC MOUSE; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; CELL LINE; CELL STRAIN 3T3; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; WHITE ADIPOSE TISSUE; ZUCKER RAT;

ANIMALIA;

3T3-L1 CELLS; ADIPOCYTES, WHITE; ANIMALS; CELL LINE; CHEMOKINES; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PPAR GAMMA; RATS; RATS, ZUCKER; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 76049086229     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912487106     Document Type: Article

References (34)

1. Imai T, et al. (2004) Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA 101:4543-4547.
2. Tontonoz P, Spiegelman BM (2008) Fat and beyond: The diverse biology of PPAR-gamma. Annu Rev Biochem 77:289-312.
3. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234.
4. Lehmann JM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956. ]
5. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106-1118.
6. Barak Y, et al. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595.
7. He W,et al. (2003) Adipose-specific peroxisome proliferator-activated receptorgamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 100:15712-15717.
8. Medina-Gomez G, et al. (2007) PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 3:e64.
9. Hevener AL, et al. (2003) Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9:1491-1497.
10. Norris AW, et al. (2003) Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608-618.
11. Hevener AL, et al. (2007) Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117:1658-1669.
12. Odegaard JI, et al. (2007) Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 447:1116-1120.
13. Chao L, et al. (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106:1221-1228.
14. Koutnikova H, et al. (2003) Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci USA 100:14457-14462.
15. Saez E, et al. (2004) PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 18:528-540.
16. Yu JG, et al. (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968-2974.
17. Kubota N, et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609.
18. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR (2007) Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56:16-23.
19. Weisberg SP, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808.
20. Xu H, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830.
21. Makowski L, et al. (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7:699-705.
22. Greaves DR, Quinn CM, Seldin MF, Gordon S (1998) Functional comparison of the murine macrosialin and human CD68 promoters in macrophage and nonmacrophage cell lines. Genomics 54:165-168.
23. Whiteman EL, Cho H, Birnbaum MJ (2002) Role of Akt/protein kinase B inmetabolism. Trends Endocrinol Metab 13:444-451.
24. Kline BJ, Saenz J, Stankovic N, Mitchell MB (2006) Polymorph and particle size control of PPAR compounds PF00287586 and AG035029. Org Process Res Dev 10:203-211.
25. Farmer SR, Auwerx J (2004) Adipose tissue: New therapeutic targets from molecular and genetic studies-IASO Stock Conference 2003 report. Obes Rev 5:189-196.
26. Rader DJ (2007) Effect of insulin resistance, dyslipidemia,andintra- abdominal adiposityon the development of cardiovascular disease and diabetes mellitus. Am J Med 120:S12-S18.
27. Chawla A, et al. (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52.
28. Li Y, Lazar MA (2002) Differential gene regulation by PPARγ agonist and constitutively active PPARγ2. Mol Endocrinol 16:1040-1048.
29. Knouff C, Auwerx J (2004) Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: Lessons from genetics and pharmacology. Endocr Rev 25:899-918.
30. Rondinone CM, et al. (1997) Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 94:4171-4175.
31. Shepherd PR, Kahn BB (1999) Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248-257.
32. Chavey C, et al. (2009) CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab 9:339-349.
33. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471.
34. Wang YX, et al. (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159-170.